ReviewHepatology communications2020
Drug-Induced Liver Injury in GI Practice.
Review in Hepatology communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 70 citations in OpenAlex.
- Extract from Eucommia ulmoides Oliv. Leaves alleviates APAP-induced acute liver injury via reshaping gut microbiota and attenuating microbial bile acids metabolism disorder.Chinese medicine · 2026Article
- Comparing Efficacy and Safety of Itraconazole Solution Versus Posaconazole for Antifungal Prophylaxis After Heart Transplant.Open forum infectious diseases · 2026Article
- Precision treatment and frontier advances of glycyrrhizin preparations in drug-induced liver injury (DILI).Frontiers in pharmacology · 2026Review
- Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review.Journal of gastroenterology and hepatology · 2024Review
- Commonly available dietary supplements, herbs and medicines - do they pose a risk for liver health? Literature review in the context of the Polish population.Clinical and experimental hepatology · 2024Review
- Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers.Cell reports. Medicine · 2023Review
- Autoimmune liver disease and multiple sclerosis: state of the art and future perspectives.Clinical and experimental medicine · 2023Review
- Article
- The exposome and liver disease - how environmental factors affect liver health.Journal of hepatology · 2023Review
- Comparing Intravenous Labetalol and Intravenous Hydralazine for Managing Severe Gestational Hypertension.Cureus · 2023Article
- Protective Effects of Apamin on Acetaminophen-Induced Hepatotoxicity in Mice.Current issues in molecular biology · 2023Article
- Probable Enoxaparin-Induced Liver Injury in a Young Patient: A Case Report of a Diagnostic Challenge.Cureus · 2023Article
- Discontinuation of immunosuppression in patients with immune-mediated drug-induced liver injury or idiopathic autoimmune hepatitis: A case-control study.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- COVID-19-related liver injury: Focus on genetic and drug-induced perspectives.World journal of virology · 2023Article
- Nonalcoholic Fatty Liver Disease Is a Risk Factor for Thiopurine Hepatotoxicity in Crohn's Disease.Crohn's & colitis 360 · 2023Article
- Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review.Annals of medicine · 2022Review
- Article
- Gut Microbiota Mediates the Therapeutic Effect of Monoclonal Anti-TLR4 Antibody on Acetaminophen-Induced Acute Liver Injury in Mice.Microbiology spectrum · 2022Article
- The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment.Metabolites · 2022Review
- Roles of Cofactors in Drug-Induced Liver Injury: Drug Metabolism and Beyond.Drug metabolism and disposition: the biological fate of chemicals · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Although drug-induced liver injury (DILI) is a rare clinical event, it carries significant morbidity and mortality, leaving it as the leading cause of acute liver failure in the United States. It is one of the most challenging diagnoses encountered by gastroenterologists. The development of various drug injury networks has played a vital role in expanding our knowledge regarding drug-related and herbal and dietary supplement-related liver injury. In this review, we discuss what defines liver injury, epidemiology of DILI, its biochemical and pathologic patterns, and management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.